# A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

> **NCT03834584** · PHASE1 · TERMINATED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** AG-636

## Key facts

- **NCT ID:** NCT03834584
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-24
- **Primary completion:** 2020-06-17
- **Final completion:** 2020-06-17
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Terminated due to sponsor decision.
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834584, "A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03834584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*